Trial Profile
A Randomised, Partially-blind, Placebo-controlled, Pilot, Dose-ranging Study To Assess The Effect Of Cannabidiol (CBD) On Liver Fat Levels In Subjects With Fatty Liver Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fatty liver
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 24 Jun 2014 New trial record